Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long IslandMarch 24, 2020
Company Ramping up Availability and Access to Testing
NEW YORK–(BUSINESS WIRE)–Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology and diagnostic company, today announced its wholly owned subsidiary, Enzo Clinical Labs, Inc., has expanded its screening services for COVID-19. Following the company’s March 6, 2020 announcement regarding the initiation of accepting specimens for novel Coronavirus (COVID-19) testing, Enzo is now directly collecting specimens at a drive-through facility by appointment in Enzo’s laboratory complex in Farmingdale, New York. This facility has been set up with support from local and state officials.
As one of the first independent drive-through testing facilities on Long Island, NY, it is easily accessible for Nassau and Suffolk County residents and is now in operation. The goal of this testing site is to help the local community improve virus surveillance and reduce pressure on the regional hospital systems.
Enzo President Barry Weiner commented: “Enzo understands and takes seriously its responsibility as a leading and resourceful diagnostic and clinical laboratory to help alleviate the present bottleneck existing around COVID-19 testing in the communities we serve during this rapidly evolving pandemic environment. We are partnering with State and Local officials to bring access and availability to the nearly eight million people in the underserved Long Island, New York, communities. Our technical staff is committed to do what it takes in providing necessary patient care. We appreciate the government and public support that has enabled Enzo to quickly establish this facility and continue to serve the Long Island community with the highest standards. We also are exploring how we can apply our many years of technical know-how and manufacturing experience to contribute to testing alternatives.”
To receive testing, patients who are concerned that they or a family member are exhibiting symptoms of COVID-19 must initially consult a physician. If directed by the physician, the patient will receive a prescription (“script”) with which the patient can make an appointment by phone for COVID-19 testing at the Farmingdale facility. Once the patient arrives at the scheduled time for the appointment, he/she will remain in their car and must present a photo-ID for verification as well as any other necessary documentation. A healthcare professional with protective gear will collect a sample using a nasal swab (similar to a flu test). The specimen will be sent to Enzo’s clinical laboratory facility for processing, and test results will be available in a timely manner through the ordering physician or, by request, directly to the patients.
Further information is available on Enzo’s website at: http://www.enzoclinicallabs.com/coronavirus
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2019. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
Enzo Biochem, Inc.
David Bench, CFO
Anreder & Company